Breaking News, Collaborations & Alliances

Charles River, Captain T Cell Sign Plasmid DNA & Viral Vector Production Program Agreement

Captain T Cell to leverage Charles River’s CGT CDMO expertise to support a T-cell immunotherapy clinical trial.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International Inc. and Captain T Cell, a spinoff from the Max Delbrück Center Berlin, Germany, have signed a plasmid DNA and retrovirus vector production program agreement.   As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisory services ahead of Captain T Cell’s plan to manufacture a ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters